Doximity (DOCS) fundamentals: P/E, valuation, undervalued?
Doximity · Health Care · ref. ETF XLV · price $30.55
In short — Doximity trades at 35.9× earnings (P/E), 19.6× forward, with a net margin of 25.5 % and revenue growth of +7 %. Read: High P/E (P/E 36 (above average)).
Is Doximity stock cheap or undervalued? A good time to buy? Here are its fundamentals — P/E, PEG, margin and income statement — to judge its valuation.
📈 1-year price
$30.55-54.4% over range
Oct 14, 25low $18.01 · high $68.5Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
26% recommend buying · 19 analysts
Valuation : High P/E — P/E 36 (above average)
Valuation
35.9
P/E (price/earnings)
19.6
Forward P/E
—
PEG
6.0
Price/book (P/B)
$5.4B
Market cap
0.85
EPS
Profitability & growth
25.5 %
Net margin
+7 %
Revenue growth
-52 %
Earnings growth
$10M
Total debt
Doximity income statement
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| 2023 | $419M | $113M | 26.9 % |
| 2024 | $475M | $148M | 31.0 % |
| 2025 | $570M | $223M | 39.1 % |
| 2026 | $645M | $196M | 30.4 % |
⚠️ Indicative financial data (Yahoo Finance), not investment advice. Amounts in $.
Frequently asked questions
What is Doximity's P/E and is the stock undervalued? What's a good P/E?
Doximity's P/E is 35.9 (forward 19.6). Below ~15 = fairly cheap, above ~30 = expensive. Our valuation verdict: "High P/E".
Is Doximity profitable?
Doximity has a net margin of 25.5 % (EPS 0.85). The company is profitable.
Is DOCS stock expensive?
Our read: "High P/E" — P/E 36 (above average). Cross-check with growth and sector.
💬 A question about Doximity? The JPI assistant answers using our backtest data.